DNA Methylation as a Predictor for Response and Progression-Free Survival in Patients With Ovarian Cancer
- To determine if DNA methylation patterns and expression of differentially methylated
genes taken before chemotherapy can predict patient outcome with regard to
- To evaluate whether DNA methylation can predict response assessed by RECIST criteria
and CA 125 response.
- To evaluate the specificity and sensitivity of predicting methylation changes in tumor
from the changes at the corresponding CpG islands in plasma.
OUTLINE: Tumor samples are collected at the time of initial laparotomy and blood is drawn
prior to surgery for DNA methylation and biomarker studies.
Changes in DNA methylation will be examined globally using DNA methylation hybridization to
microarrays and methylation specific PCR, as well as expression of genes shown to be
Observational Model: Case-Only, Time Perspective: Prospective
To determine if DNA methylation patterns and expression differentially methylated genes taken before chemotherapy can predict patient outcome with regard to progression-free survival.
Nadeem Siddiqui, MD
Scottish Gynaecological Cancer Trials Group
United Kingdom: Research Ethics Committee